

**Anzahl an Publikationen: 101**

- Originalarbeiten: 88
  - o Erstautor: 10
  - o Letztautor: 16
  - o Letter to the Editor: 14
- Editorial: 1
- Übersichtsartikel: 7
- Andere: 5

**Peer-reviewed als Erst-/ Korrespondierender Autor**

1. Heinen N, Khanal R, Westhoven S, Klöhn M, Herrmann ST, Herrmann M, Tuoc T, Ulmke PA, Nguyen HD, Nguyen HP, Steinmann E, Todt D, Brown RJP<sup>#</sup>, Sharma AD<sup>#</sup>, **Pfaender S<sup>#</sup>**. Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses. *Gut*. 2023 Dec 12:gutjnl-2023-330961. doi: 10.1136/gutjnl-2023-330961. *Impact factor: 24,5*
2. Overheu O, Lendowski S, Quast DR, Kühn D, Vidal Blanco E, Kraeft AL, Steinmann E, Kourti E, Lugnier C, Steinmann J, Reinacher-Schick A, Pfaender S. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients. *J Cancer Res Clin Oncol*. 2023 Sep;149(12):10633-10644. doi: 10.1007/s00432-023-04961-2. *Impact factor: 4,322*
3. Heinen N, Marheinecke CS, Bessen C, Blazquez-Navarro A, Roch T, Stervbo U, Anft M, Plaza-Sirvent C, Busse S, Klöhn M, Schrader J, Vidal Blanco E, Urlaub D, Watzl C, Hoffmann M, Pöhlmann S, Tenbusch M, Steinmann E, Todt D, Hagenbeck C, Zimmer G, Schmidt WE, Quast DR, Babel N, Schmitz I<sup>#</sup>, **Pfänder S<sup>#</sup>**. In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant. *Front Immunol*. 2022 Dec 21;13:1062210. doi: 10.3389/fimmu.2022.1062210. *Impact factor: 8,786*
4. Meister TL, Dreismeier M, Blanco EV, Brüggemann Y, Heinen N, Kampf G, Todt D, Nguyen HP, Steinmann J, Schmidt WE, Steinmann E, Quast DR<sup>#</sup>, **Pfaender S<sup>#</sup>**. Low risk of SARS-CoV-2 transmission by fomites - a clinical observational study in highly infectious COVID-19 patients. *J Infect Dis*. 2022 May 5;jiac170. doi: 10.1093/infdis/jiac170. Online ahead of print. *Impact factor: 7,759*
5. Meister TL, Fortmann J, Breisch M, Sengstock C, Steinmann E, Köller M, **Pfaender S<sup>#</sup>**, Ludwig A<sup>#</sup>. Nanoscale copper and silver thin film systems display differences in antiviral and antibacterial properties. *Sci Rep*. 2022 May 3;12(1):7193. doi: 10.1038/s41598-022-11212-w. *Impact factor: 4,996*
6. Meister TL, Gottsauner JM, Schmidt B, Heinen N, Todt D, Audebert F, Buder F, Lang H, Gessner A, Steinmann E, Vielsmeier V<sup>#</sup>, **Pfaender S<sup>#</sup>**, Cieplik F<sup>#</sup>. Mouthrinses against SARS-CoV-2 - High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial. *Virus Res*. 2022 May 2;316:198791. doi: 10.1016/j.virusres.2022.198791. Online ahead of print. *Impact factor: 6,286*
7. Schuhenn J, Meister TL, Todt D, Bracht T, Schork K, Billaud JN, Elsner C, Heinen N, Karakoese Z, Haid S, Kumar S, Brunotte L, Eisenacher M, Chen J, Yuan Z, Pietschmann T, Wiegmann B, Beckert H, Taube C, Le-Trilling VTK, Trilling M, Krawczyk A, Ludwig S, Sitek B, Steinmann E, Dittmer U, Lavender K<sup>#</sup>, Sutter K<sup>#\*</sup>, and **Pfaender S<sup>#\*</sup>**. Differential interferon- $\alpha$  subtype immune signatures suppress SARS-CoV-2 infection. *Proc Natl Acad Sci U S A*. 2022 Feb 22;119(8):e2111600119. doi: 10.1073/pnas.2111600119. *Impact factor: 12,776*

8. Kratzel A, Kelly JN, V'kovski P, Portmann J, Brüggemann Y, Todt D, Ebert N, Shrestha N, Plattet P, Staab-Weijnitz CA, von Brunn A, Steinmann E, Dijkman R, Zimmer G, **Pfaender S<sup>#</sup>**, Thiel V<sup>#</sup>. A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets. *PLoS Biol.* 2021 Dec 28;19(12):e3001490. doi: 10.1371/journal.pbio.3001490. *Impact factor: 9,593*
9. Heinen N, Meister TL, Klöhn M, Steinmann E, Todt D, **Pfaender S<sup>#</sup>**. Antiviral effect of budenoside against SARS-CoV-2. *Viruses* 2021, 13(7), 1411; <https://doi.org/10.3390/v13071411>. *Impact factor: 5,818*
10. Meister TL, Fortmann J, Todt D, Heinen N, Ludwig A, Brüggemann Y, Elsner C, Dittmer U, Steinmann J, **Pfaender S<sup>#</sup>**, Steinmann E<sup>#</sup>. Comparable environmental stability and disinfection profiles of the currently circulating SARS-CoV-2 variants of concern B.1.1.7 and B.1.351. *J Infect Dis.* 2021 May 16;jjab260. doi: 10.1093/infdis/jiab260. *Impact factor: 7,759*
11. Conzelmann C, Groß R, Meister TL, Todt D, Krawczyk A, Dittmer U, Stenger S, Münch J, Steinmann E, Müller JA<sup>#</sup>, **Pfaender S<sup>#</sup>**. Pasteurization Inactivates SARS-CoV-2 Spiked Breast Milk. *Pediatrics.* 2021 Jan;147(1):e2020031690. doi: 10.1542/peds.2020-031690. *Impact factor: 9,703*
12. Meister TL, Brüggemann Y, Todt D, Conzelmann C, Müller JA, Groß R, Münch J, Krawczyk A, Steinmann J, Steinmann J, **Pfaender S<sup>#</sup>** and Steinmann E<sup>#</sup>. Virucidal efficacy of different oral rinses against SARS-CoV-2. *J Infect Dis.* 2020 Jul 29;jiaa471. doi: 10.1093/infdis/jiaa471. *Impact factor: 7,759*
13. Zettl F, Meister TL, Vollmer T, Fischer B, Steinmann J, Krawczyk A, V'kovski P, Todt D, Steinmann E, **Pfaender S<sup>#</sup>** and Zimmer G<sup>#</sup>. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. *Vaccines*, (Basel). 2020 Jul 15;8(3):E386. doi: 10.3390/vaccines8030386. *Impact factor: 4,961*
14. **Pfaender S\***, Mar KB\*, Michailidis E, Kratzel A, Boys IN, V'kovski P, Fan W, Kelly JN, Hirt D, Ebert N, Stalder H, Kleine-Weber H, Hoffmann M, Heinrich Hoffmann H, Saeed M, Dijkman R, Steinmann E, Wight-Carter M, McDougal MB, Hanners NW, Pöhlmann S, Gallagher T, Todt D, Zimmer G, Rice CM, Schoggins JW, Thiel V. LY6E Impairs Coronavirus Fusion and Confers Immune Control of Viral Disease. *Nat Microbiol*, 2020 Jul 23. doi: 10.1038/s41564-020-0769-y. *Impact factor: 30,964*
15. Kratzel A, Steiner S, Todt D, V'kovski P, Brüggemann Y, Steinmann J, Steinmann E, Thiel V<sup>#</sup>, and **Pfaender S<sup>#</sup>**. Temperature-dependent Surface Stability of SARS-CoV-2. *J Infect* 2020 Jun 3;S0163-4453(20)30352-2. doi: 10.1016/j.jinf.2020.05.074. *Impact factor: 38.637*
16. Kratzel A, Todt D, V'kovski P, Steiner S, Gultom M, Thao TTN, Ebert N, Holwerda M, Steinmann J, Niemeyer D, Dijkman R, Kampf G, Drosten C, Steinmann E, Thiel V, **Pfaender S<sup>#</sup>**. Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols. *Emerg Infect Dis.* 2020 Apr 13;26(7). doi: 10.3201/eid2607.200915. *Impact factor: 16,126*
17. García-Nicolás O, V'kovski P, Vielle NJ, Ebert N, Züst R, Portmann J, Stalder H, Gaschen V, Vieyres G, Stoffel M, Schweizer M, Summerfield A, Engler O, Pietschmann T, Todt D, Alves MP, Thiel V<sup>#</sup>, **Pfaender S<sup>#</sup>**. The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. *Antimicrob Agents Chemother.* 2018 Oct 24;62(11). pii: e01206-18. doi: 10.1128/AAC.01206-18. *Impact factor: 5,938*
18. **Pfaender S\***, Helfritz F\*, Siddharta A., Todt D., Behrendt P., Heyden J., Riebesehl N., Willmann W., Jsteinmann J., Münch J., Ciesek S. and Steinmann E. Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. *Front. Microbiol.*, 27 March 2018 <https://doi.org/10.3389/fmicb.2018.00504>. *Impact factor: 6,064*

19. **Pfaender S\***, Walter S\*, Grabski E, Todt D, Bruening J, Romero-Brey I, Gather T, Brown RJ, Hahn K, Puff C, Pfankuche VM, Hansmann F, Postel A, Becher P, Thiel V, Kalinke U, Wagner B, Bartenschlager R, Baumgärtner W, Feige K, Pietschmann T, Cavalleri JM, Steinmann E. Immune protection against reinfection with nonprimate hepacivirus. *Proc Natl Acad Sci U S A*. 2017 Mar 21;114(12):E2430-E2439. doi: 10.1073/pnas.1619380114. *Impact factor: 12,776*
20. Siddharta A\*, **Pfaender S\***, Vielle NJ, Dijkman R, Friesland M, Becker B, Yang J, Engelmann M, Todt D, Windisch MP, Brill FH, Steinmann J, Steinmann J, Becker S, Alves MP, Pietschmann T, Eickmann M, Thiel V, Steinmann E. Virucidal activity of WHO-recommended formulations against enveloped viruses including Zika, Ebola and emerging Coronaviruses. *J Infect Dis*. 2017 Mar 15;215(6):902-906. doi: 10.1093/infdis/jix046. *Impact factor: 7,759*
21. **Pfaender S\***, Vielle NJ\*, Ebert N, Steinmann E, Alves MP, Thiel V. Inactivation of Zika virus in human breast milk by prolonged storage or pasteurization. *Virus Res*. 2017 Jan 15;228:58-60. doi: 10.1016/j.virusres.2016.11.025. *Impact factor: 6,286*
22. **Pfaender S\***, Grabski E\*, Detje CN, Riebesehl N, Lienenklaus S, Steinmann E, Kalinke U, Pietschmann T Hepatitis C Virus Stimulates Murine CD8 $\alpha$ -Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. *PLoS Pathog*. 2016 Jul 6;12(7):e1005736. doi: 10.1371/journal.ppat.1005736. *Impact factor: 7,464*
23. **Pfaender S\***, Walter S\*, Todt D, Behrendt P, Doerrbecker J, Wölk B, Engelmann M, Gravemann U, Seltsam A, Steinmann J, Burbelo PD, Klawonn F, Feige K, Pietschmann T, Cavalleri JM, Steinmann E. Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. *J Gen Virol*. 2015 Sep;96(9):2636-42. doi: 10.1099/vir.0.000208. *Impact factor: 5,141*
24. **Pfaender S\***, Cavalleri JM\*, Walter S, Doerrbecker J, Campana B, Brown RJ, Burbelo PD, Postel A, Hahn K, Kusuma A, Riebesehl N, Baumgärtner W, Becher P, Heim MH, Pietschmann T, Feige K, Steinmann E. Clinical course of infection and viral tissue tropism of hepatitis C virus-like non-primate hepaciviruses. *Hepatology*. 2015 Feb;61(2):448-59. *Impact factor: 17,298*
25. **Pfaender S**, Brinkmann J, Todt D, Riebesehl N, Steinmann J, Steinmann J, Pietschmann T, Steinmann E. Mechanisms of Methods for Hepatitis C Virus Inactivation. *Appl Environ Microbiol*. 2015 Mar 1;81(5):1616-21. *Impact factor: 5,005*
26. **Pfaender S**, Heyden J, Friesland M, Ciesek S, Ejaz A, Steinmann J, Steinmann J, Malarski A, Stoiber H, Tsiavaliaris G, Bader W, Jahreis G, Pietschmann T, Steinmann E. Inactivation of hepatitis C virus infectivity by human breast milk. *J Infect Dis*. 2013 Dec 15; 208(12):1943-52. *Impact factor: 7,759*

\* contributed equally # corresponding author

#### Peer-reviewed als Ko-Autor

27. Paniskaki K, Goretzki S, Anft M, Konik MJ, Meister TL, **Pfaender S**, Lechtenberg K, Vogl M, Dogan B, Dolff S, Westhoff TH, Rohn H, Felderhoff-Mueser U, Stervbo U, Witzke O, Dohna-Schwake C, Babel N. Increased SARS-CoV-2 reactive low avidity T cells producing inflammatory cytokines in pediatric post-acute COVID-19 sequelae (PASC). *Pediatr Allergy Immunol*. 2023 Dec;34(12):e14060. doi: 10.1111/pai.14060. *Impact factor: 6,377*
28. Paniskaki K, Goretzki S, Anft M, Konik MJ, Lechtenberg K, Vogl M, Meister TL, **Pfaender S**, Zettler M, Jäger J, Dolff S, Westhoff TH, Rohn H, Felderhoff-Mueser U, Stervbo U, Witzke O, Dohna-Schwake C, Babel N. Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents. *BMC Infect Dis*. 2023 Nov 22;23(1):818. doi: 10.1186/s12879-023-08805-9. *Impact factor: 3,7*
29. Paniskaki K, Konik MJ, Anft M, Heidecke H, Meister TL, **Pfaender S**, Krawczyk A, Zettler M, Jäger J, Gaeckler A, Dolff S, Westhoff TH, Rohn H, Stervbo U, Scheibenbogen C, Witzke

- O, Babel N. Low avidity circulating SARS-CoV-2 reactive CD8<sup>+</sup> T cells with proinflammatory TEMRA phenotype are associated with post-acute sequelae of COVID-19. *Front Microbiol.* 2023 Jun 2;14:1196721. doi: 10.3389/fmicb.2023.1196721. *Impact factor:* 5,2
30. Bessen C, Plaza-Sirvent C, Simsek A, Bhat J, Marheinecke C, Urlaub D, Bonowitz P, Busse S, Schumann S, Blanco EV, Skaletz-Rorowski A, Brockmeyer NH, Overheu O, Reinacher-Schick A, Faissner S, Watzl C, **Pfaender S**, Potthoff A, Schmitz I. Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV. *Front Immunol.* 2022 Dec 2;13:1049070. doi: 10.3389/fimmu.2022.1049070. *Impact factor:* 8,786
31. Faissner S, Heitmann N, Rohling R, Ceylan U, Bongert M, Plaza-Sirvent C, Marheinecke C, Pedreiturria X, Ayzenberg I, Hellwig K, Schmitz I, Pfaender S, Gold R. Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination. *Ther Adv Neurol Disord.* 2022 Dec 9;15:17562864221141505. doi: 10.1177/17562864221141505. *Impact factor:* 6,430
32. Paniskaki K, Konik MJ, Anft M, Meister TL, Marheinecke C, **Pfaender S**, Jäger J, Krawczyk A, Zettler M, Dolff S, Westhoff TH, Rohn H, Stervbo U, Witzke O, Babel N. Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination. *Front Immunol.* 2022 Oct 31;13:1031254. doi: 10.3389/fimmu.2022.1031254. *Impact factor:* 8,786
33. Schlör A, Hirschberg S, Amor GB, Meister TL, Arora P, Pöhlmann S, Hoffmann M, **Pfaender S**, Eddin OK, Kamhieh-Milz J, Hanack K. SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications. *Front Immunol.* 2022 Sep 14;13:930975. doi: 10.3389/fimmu.2022.930975. *Impact factor:* 8,786
34. Faissner S, Heitmann N, Plaza-Sirvent C, Trendelenburg P, Ceylan U, Motte J, Bessen C, Urlaub D, Watzl C, Overheu O, Reinacher-Schick A, Hellwig K, **Pfaender S**, Schmitz I, Gold R. Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination. *Front Immunol.* 2022 Aug 31;13:980526. doi: 10.3389/fimmu.2022.980526. *Impact factor:* 8,786
35. Andreica I, Blazquez-Navarro A, Sokolar J, Anft M, Kiltz U, **Pfaender S**, Vidal Blanco E, Westhoff T, Babel N, Stervbo U, Baraliakos X. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination. *RMD Open.* 2022 Sep;8(2):e002293. doi: 10.1136/rmdopen-2022-002293. *Impact factor:* 5,806
36. Fuchs FM, Bibinov N, Blanco EV, **Pfaender S**, Theiß S, Wolter H, Awakowicz P. Characterization of a robot-assisted UV-C disinfection for the inactivation of surface-associated microorganisms and viruses. *J Photochem Photobiol.* 2022 Sep;11:100123. doi: 10.1016/j.jpap.2022.100123. Epub 2022 May 1. *Impact factor:* 3,261
37. Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, Gömer A, Postmus D, Gogesch P, Niles M, Plesker R, Miskey C, Gellhorn Serra M, Breithaupt A, Hörner C, Kruij C, Ehmann R, Ivics Z, Waibler Z, **Pfaender S**, Wyler E, Landthaler M, Kupke A, Nouailles G, Goffinet C, Brown RJP, Mühlebach MD. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after T H 2-biased immunization. *Cell Rep.* 2022 Aug 3;111214. doi: 10.1016/j.celrep.2022.111214. *Impact factor:* 9,995
38. Overheu O, Lendowski S, Quast DR, Marheinecke CS, Kourti E, Lugnier C, Andreica I, Kiltz U, **Pfaender S**, Reinacher-Schick A. Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients. *J Cancer Res Clin Oncol.* 2022 Jun 22;1-8. doi: 10.1007/s00432-022-04099-7. *Impact factor:* 4,322
39. Gultom M, Kratzel A, Portmann J, Stalder H, Chanfon Bätzner A, Gantenbein H, Gurtner C, Ebert N, Gad HH, Hartmann R, Posthaus H, Zanolari P, **Pfaender S**, Thiel V, Dijkman R. Establishment of well-differentiated camelid airway cultures to study Middle East respiratory



- syndrome coronavirus. *Sci Rep*. 2022 Jun 20;12(1):10340. doi: 10.1038/s41598-022-13777-y. *Impact factor: 4,996*
40. Tangos M, Budde H, Koliijn D, Sieme M, Zhazykbayeva S, Lódi M, Herwig M, Gömöri K, Hassoun R, Robinson EL, Meister TL, Jaquet K, Kovács Á, Mustroph J, Evert K, Babel N, Fagyas M, Lindner D, Püschel K, Westermann D, Mannherz HG, Paneni F, **Pfaender S**, Tóth A, Mügge A, Sossalla S, Hamdani N. SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress. *Int J Cardiol*. 2022 Sep 1;362:196-205. doi: 10.1016/j.ijcard.2022.05.055. Epub 2022 May 26. *Impact factor: 4,039*
41. Stegmann KM, Dickmanns A, Heinen N, Blaurock C, Karrasch T, Breithaupt A, Klopffleisch R, Uhlig N, Eberlein V, Issmail L, Herrmann ST, Schreieck A, Peelen E, Kohlhof H, Sadeghi B, Riek A, Speakman JR, Groß U, Görlich D, Vitt D, Müller T, Grunwald T, **Pfaender S**, Balkema-Buschmann A, Dobbstein M. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. *iScience*. 2022 May 20;25(5):104293. doi: 10.1016/j.isci.2022.104293. Epub 2022 Apr 25. *Impact factor: 6,107*
42. Gömer A, Brown RJP, **Pfaender S**, Deterding K, Reuter G, Orton R, Seitz S, Bock CT, Cavalleri JMV, Pietschmann T, Wedemeyer H, Steinmann E, Todt D. Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance. *Virus Evol*. 2022 Feb 2;8(1):veac007. doi: 10.1093/ve/veac007. *Impact factor: 5,614*
43. Paniskaki K, Anft M, Meister TL, Marheinecke C, **Pfaender S**, Skrzypczyk S, Seibert FS, Thieme CJ, Konik MJ, Dolff S, Anastasiou O, Holzer B, Dittmer U, Queren C, Fricke L, Rohn H, Westhoff TH, Witzke O, Stervbo U, Roch T, Babel N. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. *Front Immunol*. 2022 Jan 25;13:816220. doi: 10.3389/fimmu.2022.816220. *Impact factor: 8,789*
44. Meister TL, Todt D, Brüggemann Y, Steinmann J, Banava S, Brill FHH, Steinmann J, **Pfaender S**, Steinmann E. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2. *J Hosp Infect*. 2021 Nov 6;120:9-13. doi: 10.1016/j.jhin.2021.10.019. *Impact factor: 8,944*
45. Thieme CJ, Blazquez-Navarro A, Safi L, Kaliszczyk S, Paniskaki K, Neumann IE, Schmidt K, Stockhausen M, Hörstrup J, Cinkilic O, Flitsch-Kiefner L, Meister TL, Marheinecke C, **Pfaender S**, Steinmann E, Seibert FS, Stervbo U, Westhoff TH, Roch T, Babel N. Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B.1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2. *J Am Soc Nephrol*. 2021 Nov;32(11):2725-2727. doi: 10.1681/ASN.2021050672. *Impact factor: 9,309*
46. Bormann, M.; Alt, M.; Schipper, L.; van de Sand, L.; Le-Trilling, V.T.K.; Rink, L.; Heinen, N.; Madel, R.J.; Otte, M.; Wuensch, K.; Heilingloh, C.S.; Mueller, T.; Dittmer, U.; Elsner, C.; **Pfaender, S.**; Trilling, M.; Witzke, O.; Krawczyk, A. Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro. *Viruses* 2021, 13(10), 1914; <https://doi.org/10.3390/v13101914>. *Impact factor: 5,818*
47. Brandherm L, Kobaš AM, Klöhn M, Brüggemann Y, **Pfaender S**, Rassow J, Kreimendahl S. Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding Sites in TOM70 and Recruitment of Hsp90. *Int J Mol Sci*. 2021 Aug 26;22(17):9233. doi: 10.3390/ijms22179233. *Impact factor: 6,208*
48. Todt D, Meister TL, Tamele B, Howes J, Paulmann D, Becker B, Brill FH, Wind M, Schijven J, Heinen N, Kinast V, Mhlekuide B, Goffinet C, Krawczyk A, Steinmann J, **Pfaender S**, Brüggemann Y, Steinmann E. A realistic transfer method reveals low risk of SARS-CoV-2 transmission via contaminated euro coins and banknotes. *iScience*. 2021 Aug 20;24(8):102908. doi: 10.1016/j.isci.2021.102908. Epub 2021 Jul 26. *Impact factor: 6,107*

49. Anft M, Blazquez-Navarro A, Stervbo U, Skrzypczyk S, Witzke O, Wirth R, Choi M, Hugo C, Reinke P, Meister TL, Steinmann E, **Pfaender S**, Schenker P, Viebahn R, Westhoff TH, Babel N. Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. *J Nephrol*. 2021 Jul 6;1-13. doi: 10.1007/s40620-021-01092-0. *Impact factor: 4,439*
50. Stegmann KM, Dickmanns A, Gerber S, Nikolova V, Klemke L, Manzini V, Schlösser D, Bierwirth C, Freund J, Sitte M, Lugert R, Salinas G, Meister TL, **Pfaender S**, Görlich D, Wollnik B, Groß U, Dobbelsstein M. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. *Virus Res*. 2021 Jun 3;198469. doi: 10.1016/j.virusres.2021.198469. *Impact factor: 6,286*
51. Wollschlager P, Todt D, Gerlitz N, **Pfaender S**, Bollinger T, Sing A, Dangel A, Ackermann A, Korn K, Ensser A, Steinmann E, Buhl M, Steinmann J. SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay. *Clin Microbiol Infect*. 2021 May 24;S1198-743X(21)00265-2. doi: 10.1016/j.cmi.2021.05.025. *Impact factor: 13,310*
52. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, Hoelzer B, Konik MJ, Meister TL, **Pfaender S**, Steinmann E, Berger MM, Brenner T, Kölsch U, Dolff S, Roch T, Witzke O, Schenker P, Viebahn R, Stervbo U, Westhoff TH, Babel N. The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression. *Transplantation*. 2021 Mar 18. doi: 10.1097/TP.0000000000003755. *Impact factor: 5,385*
53. Steinhauer K, Meister TL, Todt D, Krawczyk A, Paßvogel L, Becker B, Paulmann D, Bischoff B, Eggers M, **Pfaender S**, Brill FHH, Steinmann E. Virucidal efficacy of different formulations for hand and surface disinfection targeting SARS CoV-2. *J Hosp Infect*. 2021 Mar 23;S0195-6701(21)00112-2. doi: 10.1016/j.jhin.2021.03.015. *Impact factor: 8,944*
54. Steinhauer K, Meister TL, Todt D, Krawczyk A, Paßvogel L, Becker B, Paulmann D, Bischoff B, **Pfaender S**, Brill FHH, Steinmann E. Comparison of the in-vitro efficacy of different mouthwash solutions targeting SARS-CoV-2 based on the European Standard EN 14476. *J Hosp Infect* 2021 Feb 11;S0195-6701(21)00064-5. doi: 10.1016/j.jhin.2021.01.031. *Impact factor: 8,944*
55. Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, Hölzer B, Skrzypczyk S, Kohut E, Kurek J, Zapka J, Wehler P, Kaliszczuk S, Bajda S, Thieme CJ, Roch T, Konik MJ, Berger MM, Brenner T, Kölsch U, Meister TL, **Pfaender S**, Steinmann E, Tempfer C, Watzl C, Dolff S, Dittmer U, Abou-El-Enein M, Westhoff TH, Witzke O, Stervbo U, Babel N. COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a +. *Mol Ther* 2020 Dec 2;28(12):2691-2702. doi: 10.1016/j.ymthe.2020.10.001. *Impact factor: 12,910*
56. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, Hoelzer B, Konik MJ, Brenner T, Tempfer C, Watzl C, Meister TL, **Pfaender S**, Steinmann E, Dolff S, Dittmer U, Westhoff TH, Witzke O, Stervbo U, Roch T, Babel N. Robust T cell response towards spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. *Cell Rep Med*. 2020 Aug 29;100092. doi: 10.1016/j.xcrm.2020.100092. *Impact factor: 16,988*
57. Babel N, Anft M, Blazquez-Navarro A, Doevelaar AAN, Seibert FS, Bauer F, Rohn BJ, Hoelzer B, Thieme CJ, Roch T, Meister TL, **Pfaender S**, Steinmann E, Dittmer U, Schenker P, Amann K, Viebahn R, Stervbo U, Westhoff TH. Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient. *Am J Transplant*. 2020 Aug 10. doi: 10.1111/ajt.16252. *Impact factor: 8,086*
58. Thao TTN, Labroussaa F, Ebert N, V'kovski P, Stalder H, Portmann J, Kelly J, Steiner S, Holwerda M, Kratzel A, Gultom M, Schmied K, Laloli L, Hüsler L, Wider M, **Pfaender S**,

- Hirt D, Cippà V, Crespo-Pomar S, Schröder S, Muth D, Niemeyer D, Corman V, Müller MA, Drosten C, Dijkman R, Jores J, Thiel V. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. *Nature*. 2020 May 4. doi: 10.1038/s41586-020-2294-9. *Impact factor: 69,504*
59. V'kovski P, Gerber M, Kelly J, **Pfaender S**, Ebert N, Braga Lagache S, Simillion C, Portmann J, Stalder H, Gaschen V, Bruggmann R, Stoffel MH, Heller M, Dijkman R, Thiel V. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. *Elife*. 2019 Jan 11;8. pii: e42037. doi: 10.7554/eLife.42037. *Impact factor: 8,713*
60. Pfankuche VM, Hahn K, Bodewes R, Hansmann F, Habierski A, Haverkamp AK, **Pfaender S**, Walter S, Baechlein C, Postel A, Steinmann E, Becher P, Osterhaus A, Baumgärtner W, Puff C. Comparison of Different In Situ Hybridization Techniques for the Detection of Various RNA and DNA Viruses. *Viruses*. 2018 Jul 20;10(7). pii: E384. doi: 10.3390/v10070384. *Impact factor: 5,818*
61. Behrendt P, Perin P, Menzel N, Banda D, **Pfaender S**, Alves MP, Thiel V, Meulemann P, Colpitts CC, Schang LM, Vondran FWR, Anggakusuma, Manns MP, Steinmann E, Pietschmann T. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. *Antiviral Res*. 2017 Nov;147:19-28. doi: 10.1016/j.antiviral.2017.09.006. *Impact factor: 10,103*
62. Reichert C., Campe A., Walter S., **Pfaender S.**, Welsch K., Ruddat I., Sieme H., Feige K., Steinmann E., Cavalleri J.-M.V. Frequent occurrence of nonprimate hepacivirus infections in Thoroughbred breeding horses - a cross-sectional study for the occurrence of infections and potential risk factors, *Veterinary Microbiology* (2017), doi.org/10.1016/j.vetmic.2017.03.030. *Impact factor: 3,246*
63. Siddharta A, **Pfaender S**, Malassa A, Doerrbecker J, Anggakusuma, Engelmann M, Nugraha B, Steinmann J, Todt D, Vondran FW, Mateu-Gelabert P,67 C, Steinmann E. Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs. *Sci Rep*. 2016 Nov 18;6:36619. doi: 10.1038/srep36619. *Impact factor: 4,996*
64. Walter S, Rasche A, Moreira-Soto A, **Pfaender S**, Bletsa M, Corman VM, Aguilar-Setien A, García-Lacy F, Hans A, Todt D, Schuler G, Shnaiderman-Torban A, Steinman A, Roncoroni C, Veneziano V, Rusenova N, Sandev N, Rusenov A, Zapryanova D, García-Bocanegra I, Jores J, Carluccio A, Veronesi MC, Cavalleri JM, Drosten C, Lemey P, Steinmann E, Drexler JF. Differential infection patterns and recent evolutionary origins of equine hepaciviruses in donkeys. *J Virol*. 2016 Dec 16;91(1). pii: e01711-16. *Impact factor: 6,549*
65. Gather T, Walter S, **Pfaender S**, Todt D, Feige K, Steinmann E, Cavalleri JM. Acute and chronic infections with nonprimate hepacivirus in young horses. *Vet Res*. 2016 Sep 22;47(1):97. *Impact factor: 3,829*
66. Gather T, Walter S, Todt D, **Pfaender S**, Brown RJ, Postel A, Becher P, Moritz A, Hansmann F, Baumgaertner W, Feige K, Steinmann E, Cavalleri JV Vertical transmission of hepatitis C virus-like nonprimate hepacivirus in horses. *J Gen Virol*. 2016 Oct;97(10):2540-2551. doi: 10.1099/jgv.0.000561. *Impact factor: 5,141*
67. Walter S, Bollenbach A, Doerrbecker J, **Pfaender S**, Brown RJ, Vieyres G, Scott C, Foster R, Kumar A, Zitzmann N, Griffin S, Penin F, Pietschmann T, Steinmann E. Ion-channel function and cross-species determinants in viral assembly of nonprimate hepacivirus p7. *J Virol*. 2016 Apr 29;90(10):5075-5089. doi: 10.1128/JVI.00132-16. *Impact factor: 6,549*
68. Postel A, Cavalleri JM, **Pfaender S**, Walter S, Steinmann E, Fischer N, Feige K, Haas L and Becher P. Frequent presence of hepaci and pegiviruses in commercial equine serum pools. *Veterinary Microbiology* 2015 <http://dx.doi.org/10.1016/j.vetmic.2015.10.032>. *Impact factor: 3,246*

69. Walker A, Skibbe K, Steinmann E, **Pfaender S**, Kuntzen T, Megger DA, Groten S, Sitek B, Lauer GM, Kim AY, Pietschmann T, Allen TM, Timm J. Distinct escape pathway by HCV genotype 1a from a dominant CD8<sup>+</sup> T cell response by selection of altered epitope processing. *J Virol*. 2015 Oct 7. pii: JVI.01993-15. *Impact factor: 6,549*
70. Stöhr S, Costa R, Sandmann L, Westhaus S, **Pfaender S**, Anggakusuma, Dazert E, Meuleman P, Vondran FW, Manns MP, Steinmann E, von Hahn T, Ciesek S. Host cell mTORC1 is required for HCV RNA replication. *Gut*. 2016 Dec;65(12):2017-2028. doi: 10.1136/gutjnl-2014-308971. *Impact factor: 31,840*
71. Grabski E, Wappler I, **Pfaender S**, Steinmann E, Haid S, Dzionek A, Pietschmann T, Kalinke U. Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus induced interferon- $\alpha$  responses of plasmacytoid dendritic cells. *J Virol*. 2015 Mar 15;89(6):3200-8. *Impact factor: 6,549*
72. Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, **Pfaender S**, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. *Gut*. 2014 Jul 63(7):1137-49. *Impact factor: 31,840*
73. Doerrbecker J, Meuleman P, Kang J, Riebesehl N, Wilhelm C, Friesland M, **Pfaender S**, Steinmann J, Pietschmann T, Steinmann E. Thermostability of seven hepatitis C virus genotypes in vitro and in vivo. *J Viral Hepat*. 2013 Jul;20(7):478-85. *Impact factor: 3,517*
74. von Hahn T, Schiene-Fischer C, Van ND, **Pfaender S**, Karavul B, Steinmann E, Potthoff A, Strassburg C, Hamdi N, Abdelaziz AI, Sarrazin C, Müller T, Berg T, Trépo E, Wedemeyer H, Manns MP, Pietschmann T, Ciesek S. Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. *Gastroenterology*. 2012 Aug;143(2):439-47. *Impact factor: 33,883*

#### Letter to the Editor

75. Simsek A, Bessen C, Meister TL, Urlaub D, Skaletz-Rorowski A, Brockmeyer NH, Overheu O, Reinacher-Schick A, Faissner S, Watzl C, **Pfaender S**, Schmitz I, Potthoff A, Plaza-Sirvent C. Humoral and cellular immune responses to repeated SARS-CoV-2 infection and vaccination in an individual living with HIV. *J Eur Acad Dermatol Venereol*. 2023 Mar 13. doi: 10.1111/jdv.19036.
76. Anft M, Skrzypczyk S, Frahnert M, Fricke L, Zapka J, Kühn D, Koos B, Adamzik M, **Pfaender S**, Stervbo U, Westhoff TH, Babel N. Immunogenicity of Bivalent Omicron BA.4/5-Adapted Vaccine in Hemodialysis Patients. *Kidney Int Rep*. 2023 Apr;8(4):939-941. doi: 10.1016/j.ekir.2023.01.020. *Impact factor: 4,164*
77. Anft M, Skrzypczyk S, Frahnert M, Fricke L, Zapka J, Kühn D, Koos B, Adamzik M, **Pfaender S**, Stervbo U, Westhoff TH, Babel N. Significant Fade of Neutralizing Antibodies and Stable Cellular Immunity in 4 Times COVID-19 Vaccinated Noninfected Compared to COVID-19 Convalescent and 3 Times Vaccinated Hemodialysis Patients. *Kidney Int Rep*. 2023 Mar;8(3):685-687. doi: 10.1016/j.ekir.2023.01.005. *Impact factor: 4,164*
78. Anft M, Skrzypczyk S, Frahnert M, Fricke L, Zapka J, Kühn D, Koos B, Adamzik M, **Pfaender S**, Stervbo U, Westhoff TH, Babel N. Immunogenicity of bivalent omicron BA.4/5 adapted vaccine in hemodialysis patients. *Kidney Int Rep*. 2023 Jan 25. doi: 10.1016/j.ekir.2023.01.020. *Impact factor: 4,164*
79. Anft M, Skrzypczyk S, Frahnert M, Fricke L, Zapka J, Kühn D, Koos B, Adamzik M, **Pfaender S**, Stervbo U, Westhoff TH, Babel N. Significant fade of neutralizing antibodies and stable cellular immunity in 4 times COVID-19 vaccinated non-infected compared to COVID-19 convalescent and 3 times vaccinated hemodialysis patients. *Kidney Int Rep*. 2023 Jan 9. doi: 10.1016/j.ekir.2023.01.005. *Impact factor: 4,164*



80. Anft M, Paniskaki K, Giglio T, Wellenkötter J, Blazquez-Navarro A, Meister TL, Roch T, Giesecke-Thiel C, Westhoff TH, Stervbo U, **Pfaender S**, Cinkilic O, Babel N. SARS-CoV-2 vaccination improves HBV seroconversion rate through heterologous immunity. *Kidney Int.* 2022 Nov 1;S0085-2538(22)00920-6.doi: 10.1016/j.kint.2022.10.012. *Impact factor: 18,998*
81. Blazquez-Navarro A, Mittmann L, Thieme CJ, Anft M, Paniskaki K, Doevelaar A, Seibert FS, Hoelzer B, Konik MJ, Berger MM, Brenner T, Tempfer C, Watzl C, Meister TL, **Pfaender S**, Steinmann E, Dolff S, Dittmer U, Witzke O, Stervbo U, Roch T, Or-Guil M, Westhoff TH, Babel N. Impact of low eGFR on the immune response against COVID-19. *J Nephrol.* 2022 Jul 2.doi: 10.1007/s40620-022-01374-1. *Impact factor 4,439*
82. Blazquez-Navarro A, Safi L, Meister TL, Thieme CJ, Kaliszczyk S, Paniskaki K, Stockhausen M, Hörstrup J, Cinkilic O, Flitsch-Kiefner L, Marheinecke C, Steinmann E, Seibert FS, Stervbo U, Westhoff TH\*, **Pfaender S\***, Roch T\*, Babel N<sup>#</sup>. Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2 vaccinated dialysis patients. *Kidney Int.* 2021 Jul 14;S0085-2538(21)00680-3. doi: 10.1016/j.kint.2021.07.006. *Impact factor: 18,998*
83. Anft M, Blazquez-Navarro A, Frahnert M, Fricke L, Meister TL, Roch T, Stervbo U, **Pfaender S**, Westhoff TH, Babel N. Inferior cellular and humoral immunity against Omicron and Delta VOC compared to SARS-CoV-2 wild-type in hemodialysis patients immunized with four SARS-CoV-2 vaccine doses. *Kidney Int.* 2022 May 14;S0085-2538(22)00367-2.doi: 10.1016/j.kint.2022.05.004. *Impact factor: 18,998*
84. Cinkilic O, Anft M, Blazquez-Navarro A, Meister TL, Roch T, Stervbo U, **Pfaender S**, Westhoff TH, Babel N. Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses. *Kidney Int.* 2022 Mar 14;S0085-2538(22)00204-6. doi: 10.1016/j.kint.2022.03.005. *Impact factor: 18,998*
85. Roch T, Rohn B, Blazquez-Navarro A, Meister TL, Blanco EV, Paniskaki K, Wellenkötter J, Zgoura P, Giglio T, **Pfaender S**, Stervbo U, Viebahn R, Cinkilic O, Westhoff TH, Babel N. A vector-based vaccine dose after three doses of mRNA-based COVID-19 vaccination does not substantially improve humoral SARS-CoV-2 immunity in renal transplant recipient. *Kidney Int Rep* 2022 Feb doi: 10.1016/j.ekir.2022.01.1068. *Impact factor: 10,612*
86. Stervbo U, Blazquez-Navarro A, Blanco EV, Safi L, Meister TL, Paniskaki K, Stockhausen M, Marheinecke C, Zimmer G, Wellenkötter J, Giglio T, Arora P, Pöhlmann S, Hoffmann M, Seibert FS, **Pfaender S**, Roch T, Westhoff TH, Cinkilic O, Babel N. Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease. *Kidney Int.* 2021 Oct 4;S0085-2538(21)00925-X. doi: 10.1016/j.kint.2021.09.015. *Impact factor: 18,998*
87. Westhoff TH, Seibert FS, Anft M, Blazquez-Navarro A, Skrzypczyk S, Zgoura P, Meister TL, **Pfaender S**, Stumpf J, Hugo C, Viebahn R, Roch T, Stervbo U, Babel N. A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse. *Kidney Int* 2021 Sep 9;S0085-2538(21)00850-4. doi: 10.1016/j.kint.2021.09.001. *Impact factor: 18,998*
88. Thieme CJ, Abou-El-Enein M, Fritsche E, Anft M, Paniskaki K, Skrzypczyk S, Doevelaar A, Elsallab M, Brindle N, Blazquez-Navarro A, Seibert FS, Meister TL, **Pfaender S**, Steinmann E, Witzke O, Westhoff TH, Stervbo U, Heine G, Roch T, Babel N. Detection of SARS-CoV-2 Specific Memory B cells to Delineate Long-Term COVID-19 Immunity. *Allergy* 2021 Mar 25. doi: 10.1111/all.14827. *Impact factor 14,710*

## Editorial

89. Brüggemann Y, Kratzel A, Almeida L, Kelly JN, Thiel V<sup>#</sup>, **Pfaender S<sup>#</sup>**. Conserved requirement of autophagy-related effectors during coronavirus replication. *Autophagy*. 2022 Jul 24;1-3. doi: 10.1080/15548627.2022.2100617. *Impact factor: 13,391*

#### Peer-reviewed: Übersichtsartikel

90. Kampf G, **Pfaender S**, Goldmann E, Steinmann E. SARS-CoV-2 Detection Rates from Surface Samples Do Not Implicate Public Surfaces as Relevant Sources for Transmission. *Hygiene* 2021, 1(1), 24-40; <https://doi.org/10.3390/hygiene1010003>. *Impact Factor: none*
91. Heinen N, Klöhn M, Steinmann E, **Pfaender S**. In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease. *Viruses*. 2021 Apr 28;13(5):792. doi: 10.3390/v13050792. *Impact factor: 5,818*
92. Kampf G, Brüggemann Y, Kaba HEJ, Steinmann J, **Pfaender S**, Scheithauer S, Steinmann E. Potential sources, modes of transmission and effectiveness of prevention measures against SARS-CoV-2. *J Hosp Infect*. 2020 Sep 18;S0195-6701(20)30437-0. *Impact factor: 8,944*
93. Kampf G, Todt D, **Pfaender S**, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect*. 2020 Mar;104(3):246-251. doi: 10.1016/j.jhin.2020.01.022. *Impact factor: 8,944*
94. Alves MP<sup>#</sup>, Vielle NJ, Thiel V<sup>#</sup>, **Pfaender S<sup>#</sup>**, Research Models and Tools for the Identification of Antivirals and Therapeutics against Zika Virus Infection. *Viruses*. 2018 Oct 30;10(11). pii: E593. doi: 10.3390/v10110593. *Impact factor: 5,818*
95. **Pfaender S**, von Hahn T, Steinmann J, Ciesek S, Steinmann E. Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy. *Rev Med Virol*. 2016 Sep;26(5):330-9. doi: 10.1002/rmv.1890. *Impact factor: 11,043*
96. **Pfaender S**, Brown RJ., Pietschmann T., Steinmann E. Natural Reservoirs for Homologs of Hepatitis C Virus. *Emerging Microbes & Infections* (2014) **3**, e21. *Impact factor: 5,842*

#### Reviewed: Andere

97. Held A, Dellweg D, Köhler D, **Pfaender S**, Scheuch G, Schumacher S, Steinmann E, Weingartner E, Weinzierl B, Asbach C. Interdisziplinäre Perspektiven zur Bedeutung der Aerosolübertragung für das Infektionsgeschehen von SARS-CoV-2. *Das Gesundheitswesen*. Manuskript-ID GESU-2021-10-1535-SN.R1.
98. Brüggemann Y, Elsner C, **Pfaender S<sup>#</sup>**. Novel antiviral strategies against emerging arbovirus infections. *Methods and Principles in Medicinal Chemistry*. Volume 80, WILEY-VCH. Print ISBN: 978-527-34337-9.
99. Klöhn M, Steinmann E, **Pfaender S<sup>#</sup>**. Akut- und Langzeitimmunität – Was serologische Tests wirklich über den Immunstatus preisgeben / Acute-and Long-term immunity - What serological tests really reveal about the immune status". Georg Thieme Verlag KG, *Aktuelle Kardiologie*, AktKar-KU-2020-11-0238
100. Meister TL, Brüggemann Y, Todt D, **Pfaender S**, Steinmann E. Reply to Lamarca et al. *J Infect Dis*. Volume 223, Issue 6, 15 March 2021, Pages 1114–1115, <https://doi.org/10.1093/infdis/jiaa795>
101. **Pfaender S<sup>#</sup>**. Respiratorische Virusinfektionen: Mechanismen der saisonalen Ausbreitung. *Dtsch Arztebl* 2020; 117(37): [10]; DOI: 10.3238/PersInfek.2020.09.11.05

\* contributed equally <sup>#</sup> corresponding author